Erythema annulare centrifugum following SARS‐CoV‐2 infection in a pediatric patient

Abstract

Dermatologists and oncologists need to be aware of the existence of skin toxicities due to PARP inhibitors and of the possibility of switching PARP inhibitors as an effective approach to prevent the therapeutic discontinuation and therefore maintain the benefits of these targeted therapies.

Erythema annulare centrifugum in the setting of COVID‐19 infection: A case report and literature review

“…To our knowledge, there have been only four case reports, including ours, for EAC encountered in association with COVID‐19 infection; one of whom resolved with oral doxycycline, 7 and three others improved with topical steroids and/or antihistamine. 8 , 9 Except one child case, 8 their skin lesions appeared about 1 week after the onset of COVID‐19 infection and disappeared within 1 month, suggesting the consequence of viral infection itself and/or preceded antiviral therapy. Except our case, however, the remaining three cases have received neither antiviral therapy including remdesivir nor any of drugs.…”

“…To our knowledge, there have been only four case reports, including ours, for EAC encountered in association with COVID-19 infection; one of whom resolved with oral doxycycline, 7 and three others improved with topical steroids and/or antihistamine. 8,9 Except one child case,…”